<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16807">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888093</url>
  </required_header>
  <id_info>
    <org_study_id>201607769</org_study_id>
    <nct_id>NCT02888093</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension</brief_title>
  <official_title>A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Urogynecological Association (IUGA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterosacral ligament suspension (USLS) is a commonly performed, vaginal surgery for the
      correction of female pelvic organ prolapse. The original description of this procedure
      included the use of permanent sutures. However, permanent suture use in this vaginal
      application can result in some minor complication such as persistent vaginal spotting,
      vaginal discharge and dyspareunia. Subsequent reports on this procedure have utilized
      delayed-absorbable sutures in order to avoid these complications. Retrospective studies are
      conflicting as to whether or not absorbable suture provides as durable an anatomic outcome
      as permanent suture. There are currently no high-quality, prospective studies that have
      evaluated outcomes of permanent and absorbable suture for uterosacral ligament suspension.

      This study will recruit women scheduled to undergo USLS with or without other prolapse or
      anti-incontinence procedures. Participants will be randomized 1:1 to permanent or absorbable
      suture. Follow up will occur at 6 weeks and 12 months post-operatively. The primary outcome
      will be Pelvic Organ Prolapse Quantification Exam (POP-Q) point C as measured at the 12
      month follow up visit. Subjects and assessors will be blinded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Organ Prolapse Quantification Exam (POP-Q) point C</measure>
    <time_frame>12 months</time_frame>
    <description>Non-inferiority of POP-Q point C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suture-related complications</measure>
    <time_frame>6 weeks and 12 months</time_frame>
    <description>Granulation, pain, bleeding, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic prolapse outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>PFDI-20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Cystocele</condition>
  <condition>Uterine Prolapse</condition>
  <arm_group>
    <arm_group_label>Absorbable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Permanent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)</intervention_name>
    <arm_group_label>Absorbable</arm_group_label>
    <arm_group_label>Permanent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for uterosacral ligament suspension (USLS)

        Exclusion Criteria:

          -  Non-English speaking

          -  Prisoner

          -  Cognitive impairment precluding informed consent

          -  Planned hysteropexy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph T Kowalski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph T Kowalski, MD</last_name>
    <phone>3193564839</phone>
    <email>joseph-kowalski@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine S Bradley, MD, MSCE</last_name>
    <phone>3193561534</phone>
    <email>catherine-bradley@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph T Kowalski, MD</last_name>
      <phone>319-356-4839</phone>
      <email>joseph-kowalski@uiowa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>August 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Joseph Kowalski</investigator_full_name>
    <investigator_title>Female Pelvic Medicine and Reconstructive Surgery, Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
